Richard H. Scheller - Jan 30, 2025 Form 3 Insider Report for Maze Therapeutics, Inc. (MAZE)

Role: Director
Signature: /s/ Courtney Phillips, as attorney-in-fact
Stock symbol: MAZE
Transactions as of: Jan 30, 2025
Transactions value $: $0
Form type: 3
Date filed: 1/30/2025, 04:35 PM
Previous filing: Aug 28, 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MAZE	Common Stock						20.7K	Jan 30, 2025	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	MAZE	Stock Option (Right to Buy)							Jan 30, 2025	Common Stock	8.11K	$10.42	Direct	F1
holding	MAZE	Stock Option (Right to Buy)							Jan 30, 2025	Common Stock	5.7K	$10.42	Direct	F2
holding	MAZE	Stock Option (Right to Buy)							Jan 30, 2025	Common Stock	9.09K	$10.42	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on July 1, 2022.
F2	The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
F3	The option vested or vests as to 1/36th of the total award monthly, with the first tranche vesting on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.